pharmaphorum
JUNE 21, 2021
It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot. Now, the German company has issued a reminder of its original R&D mission with the start of the first phase 2 trial of BNT111 – the first of several cancer vaccine candidates – in patients with skin cancer.
Pharma Times
JUNE 22, 2021
An extra £40m will go toward enhancing mental health services for children and young people
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
JUNE 22, 2021
Annual Drug Patent Expirations for AIRDUO+RESPICLICK Airduo Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from three suppliers. There are twenty-one…. The post New patent expiration for Teva Pharm drug AIRDUO RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Outsourcing Pharma
JUNE 22, 2021
The pharmaceutical company reports favorable results in a recent study exploring mobocertinib in treating certain non-small cell lung cancer patients.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
JUNE 22, 2021
Sanofi and Translate Bio have started a first clinical trial of an mRNA-based seasonal flu vaccine, adding to the COVID-19 shot already in testing as part of their three-year old collaboration. Enthusiasm for mRNA vaccines is riding high amid the successful rollout of COVID-19 shots from Pfizer/BioNTech and Moderna, and attention is now turning toe the possibility of using the approach to tackle other infectious diseases.
Pharma Times
JUNE 21, 2021
Children treated with gene therapy prior to symptom presentation achieved motor milestones not seen in the natural history of SMA
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
NY Times
JUNE 19, 2021
Singapore is allowing 24 private health clinics to administer the vaccine. But it has not added it to the national vaccination program.
pharmaphorum
JUNE 25, 2021
Former Cognoa executive Andy Molnar has been appointed chief executive of the Digital Therapeutics Alliance, a global trade association for companies developing evidence-based DTx products. Molnar, who served as vice president of market access and government affairs at Cognoa, joins the four-year-old trade association at a time when the potential of using DTx to deliver remote healthcare has been thrust into the spotlight by the coronavirus pandemic.
Pharma Times
JUNE 21, 2021
Aubagio has been authorised for the treatment of paediatric patients aged ten to 17 years living with RRMS
Drug Patent Watch
JUNE 20, 2021
Annual Drug Patent Expirations for DICLEGIS Diclegis is a drug marketed by Duchesnay and is included in one NDA. It is available from three suppliers. There is one patent protecting…. The post New patent expiration for Duchesnay drug DICLEGIS appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
NY Times
JUNE 22, 2021
The Alzheimer’s treatment will cost $56,000 per patient, and millions may use it. The result: “crazy numbers” for Medicare.
pharmaphorum
JUNE 22, 2021
AstraZeneca’s SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will now have to share the market with Boehringer Ingelheim and Eli Lilly’s rival therapy Jardiance. . The European Commission has become the first regulator to approved Jardiance (empagliflozin) as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF), also known as systolic heart failure.
Pharma Times
JUNE 22, 2021
First oral blood thinning drug approved for paediatric patients in the US
Drug Patent Watch
JUNE 22, 2021
Annual Drug Patent Expirations for PROAIR+RESPICLICK Proair Respiclick is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from two suppliers. There are…. The post New patent expiration for Teva Branded drug PROAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Outsourcing Pharma
JUNE 24, 2021
The project will use the artificial intelligence specialistâs cell-centered models and deconvolutions to gain insights for each individual asthma endotype.
pharmaphorum
JUNE 21, 2021
The NHS App has soared in popularity since it was updated in May to allow people to record their COVID-19 vaccination status, with more than 2 million new signups taking the total number of users to 6 million. . The app – which should not be confused with the NHS COVID-19 track and trace app – was used by five million people in the last month, according to the Department of Health and Social Care.
Pharma Times
JUNE 21, 2021
Approval makes Astepro the first and only OTC steroid free antihistamine nasal spray available in the US
Drug Patent Watch
JUNE 22, 2021
Annual Drug Patent Expirations for NOCDURNA Nocdurna is a drug marketed by Ferring Pharms Inc and is included in one NDA. It is available from one supplier. There are nine…. The post New patent for Ferring Pharms drug NOCDURNA appeared first on DrugPatentWatch - Make Better Decisions.
NY Times
JUNE 22, 2021
Restrictions on mifepristone mean patients are not getting the best treatment.
pharmaphorum
JUNE 25, 2021
Sanofi and Regeneron’s checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-small cell lung cancer (NSCLC). The approval of Libtayo (cemiplimab) in advanced NSCLC is for first-line treatment of patients with 50% or more PD-L1 expression and no EGFR, ALK or ROS1 aberrations, taking the drug into a large market dominated by Merck & Co/MSD’s rival checkpoint inhibitor Key
Pharma Times
JUNE 24, 2021
Collaboration aims to accelerate Novartis’ use of data and digital technologies
Outsourcing Pharma
JUNE 24, 2021
The annual event (scheduled July 12-16 online) will feature educational sessions, presentations, and networking opportunities for drug manufacturing pros.
NY Times
JUNE 20, 2021
Shut out from mainstream medicine, some immigrants are buying expensive, unproven Covid therapies from “wellness” clinics or turning to the black market.
pharmaphorum
JUNE 21, 2021
Sanofi’s Aubagio has become the first oral therapy approved for first-line use in children and adolescents with multiple sclerosis in the EU, a few days after the same indication was turned down by the FDA in the US. The results of the phase 3 TERIKIDS trial were deemed adequate to get a green light from the European Commission, but were rejected as inadequate last week by the FDA, which has asked Sanofi to carry out another trial in paediatric MS.
Pharma Times
JUNE 25, 2021
Findings of the latest study assessing the test back its use as a screening tool, researchers say
Drug Patent Watch
JUNE 23, 2021
Annual Drug Patent Expirations for SOOLANTRA Soolantra is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from three suppliers. There are eleven…. The post New patent for Galderma Labs drug SOOLANTRA appeared first on DrugPatentWatch - Make Better Decisions.
Outsourcing Pharma
JUNE 23, 2021
The research collaboration is aimed at studying disparities in care with a focus on multiple myeloma, a cancer disproportionately affecting Black patients.
pharmaphorum
JUNE 23, 2021
GlaxoSmithKline’s pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory syncytial virus (RSV) vaccine and new blood cancer drug Blenrep. By 2031, the UK drugmaker expects sales to top £33 billion ($46 billion), despite facing a patent cliff for big-selling HIV drugs including dolutegravir towards the end of this decade, with double-digit profit growth expected over the next
Pharma Times
JUNE 23, 2021
Strategy includes proposals for patients to easily access their test results, medication lists, procedures and care plans
NY Times
JUNE 21, 2021
Even those who supported the F.D.A.’s approval of the controversial new drug said authorizing it for anyone with Alzheimer’s disease was much too broad.
Outsourcing Pharma
JUNE 22, 2021
The pharma firm reports its Veklury (remdesivir) led to a reduction in mortality rate among hospitalized patients in three analyses of real-world data.
pharmaphorum
JUNE 24, 2021
Poor medication adherence is both a costly issue for pharma manufacturers – with some estimating a loss of $600 billion each year – and a deadly issue for patients, with more than 100k preventable deaths estimated from patients not taking medications correctly, or at all. Tara Herington explores why medication non-adherence is a complex issue. Communication is ever evolving and comes with distinct challenges for the pharma industry.
Pharma Times
JUNE 21, 2021
Lu-PSMA-617 is a potential treatment for metastatic castration-resistant prostate cancer
NY Times
JUNE 24, 2021
The experimental treatment relies on radioactive molecules that seek out tumor cells, a strategy that may be useful against other cancers.
Drug Patent Watch
JUNE 25, 2021
Annual Drug Patent Expirations for OXBRYTA Oxbryta is a drug marketed by Global Blood Theraps and is included in one NDA. There are eight patents protecting this drug. This drug…. The post New patent for Global Blood drug OXBRYTA appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
145 
Let's personalize your content